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Abstract
Light induced retinal degeneration (LIRD) is a useful model that resembles human retinal
degenerative diseases. The modulation of adenosine A1 receptor is neuroprotective in dif-
ferent models of retinal injury. The aim of this work was to evaluate the potential neuropro-
tective effect of the modulation of A1 receptor in LIRD. The eyes of rats intravitreally injected
with N6-cyclopentyladenosine (CPA), an A1 agonist, which were later subjected to continu-
ous illumination (CI) for 24 h, showed retinas with a lower number of apoptotic nuclei and a
decrease of Glial Fibrillary Acidic Protein (GFAP) immunoreactive area than controls. Lower
levels of activated Caspase 3 and GFAP were demonstrated by Western Blot (WB) in
treated animals. Also a decrease of iNOS, TNFα and GFAP mRNA was demonstrated by
RT-PCR. A decrease of Iba 1+/MHC-II+ reactive microglial cells was shown by immunohis-
tochemistry. Electroretinograms (ERG) showed higher amplitudes of a-wave, b-wave and
oscillatory potentials after CI compared to controls. Conversely, the eyes of rats intravitreally
injected with dipropylcyclopentylxanthine (DPCPX), an A1 antagonist, and subjected to CI
for 24 h, showed retinas with a higher number of apoptotic nuclei and an increase of GFAP
immunoreactive area compared to controls. Also, higher levels of activated Caspase 3 and
GFAP were demonstrated by Western Blot. The mRNA levels of iNOS, nNOS and inflam-
matory cytokines (IL-1β and TNFα) were not modified by DPCPX treatment. An increase of
Iba 1+/MHC-II+ reactive microglial cells was shown by immunohistochemistry. ERG showed
that the amplitudes of a-wave, b-wave, and oscillatory potentials after CI were similar to con-
trol values. A single pharmacological intervention prior illumination stress was able to swing
retinal fate in opposite directions: CPA was neuroprotective, while DPCPX worsened retinal
damage. In summary, A1 receptor agonism is a plausible neuroprotective strategy in LIRD.
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Introduction
Human retinal degenerative diseases are important disabling conditions. Among them, age-
related macular degeneration (AMD) is the first cause of acquired blindness in developed
countries [1]. In the US, the prevalence of AMD is similar to that of all invasive cancers com-
bined and more than double the prevalence of Alzheimer´s disease [2]. The treatment of
advanced neovascular AMD (“wet¨ variant) consists mainly on the use of monoclonal antibod-
ies against vascular endothelial growth factor (VEGF) but the ¨dry¨ variant of AMD has no
reliable treatment yet. Current treatments for dry AMD slow down or prevent additional
vision loss to some extent but they do not restore lost vision. The majority of patients require
indefinite treatment or demonstrate disease progression despite therapies [2]. A meta-analysis
shows that 20–25% of unilateral AMD cases, and up to 50% of unilateral late AMD cases prog-
ress to bilateral in 5 years [3]. These evidences show the importance of exploring other phar-
macological tools to deal with retinal degenerative diseases. Recent articles have also shown
the neuroprotective effect of peptides such as pituitary adenylate cyclase-activating peptide
(PACAP) and the octapeptide NAP, derived from activity-dependent neuropeptide protein
(ADNP), in rat diabetic retinopathy which counteract the up-regulation of VEGF [4, 5].
Animal models of retinal degenerative diseases must be employed to test potential pharma-
cological treatments. Light induced retinal degeneration (LIRD) has been widely used to study
degenerative diseases of the retina [6–12]. The main hallmarks of the LIRD model are similar
to some of those detected in human AMD, juvenile macular degeneration or retinitis pigmen-
tosa. The degenerative process starts in the outer retina as continuous illumination (CI) pro-
duces photoreceptor (PH) degeneration, apoptosis in the outer nuclear layer (ONL), increased
phagocytosis by the retinal pigment epithelium (RPE) and synaptic degeneration in the outer
plexiform layer (OPL) [7, 13–17]. Conversely, in other degenerative diseases such as diabetic
retinopathy, retinopathy of prematurity, glaucoma, and ischemia, degeneration starts in the
inner retina and affects primarily to inner nuclear layer, ganglion cell layer and optic nerves
[18–20].
In our hands, treating albino rats (Sprague Dawley) with white light (12 klux) produces a
peak of NO after one day of continuous illumination [10], an increase of glucocorticoids, a
great number of apoptotic nuclei in the outer nuclear layer after 2 days of continuous illumina-
tion [7], and the complete loss of photoreceptors after 7 days of continuous illumination [17].
Adenosine is a non-classical transmitter found in the extracellular space as a consequence
of ATP breakdown by ectonucleosidases or through translocation by membrane nucleoside
transporters. Adenosine binds to G protein coupled receptors belonging to the P1 family of
receptors known as A1, A2A, A2B and A3 receptors [21, 22]. Different autoradiographic and
in situ hybridization studies have shown the localization of adenosine receptors in the retina of
rabbits, mice, rats, monkeys, and humans [23–26].
In recent years, the modulation of adenosine receptors has emerged as a potential neuro-
protective strategy to treat a wide range of insults and degenerative diseases of the CNS [27].
A1 receptor agonists have been reported to be neuroprotective in animal models of epilepsy,
inflammatory, hypoxic, and degenerative diseases of the CNS [28–30]. In humans with Alzhei-
mer´s disease, A1R expression rises and is associated with number of amyloid plaques and Tau
phosphorylation. It was suggested that adenosine could slow down the progression of Alzhei-
mer´s disease [31].
Adenosine release is an important component of the ischemic/hypoxic insult to the retina
[32, 33], where it probably produces hyperhemia that protects neurons from glutamate toxicity
[34]. The neuroprotective role of adenosine after the ischemic injury of the retina is mediated
via A1R and/or A2R [35]. Furthermore, recent works have demonstrated the neuroprotective
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role of A2A receptor antagonists against damage induced by retinal ischemia both in animal
models of ischemia-reperfusion and in primary microglial cultures submitted to elevated
hydrostatic pressure [36, 37]. Although there is an extensive knowledge about the neuropro-
tective role of adenosine in different models of retinal degenerations, including ischemic and
diabetic retinopathy [38], little is known about the role of adenosine in degenerative diseases
of the outer retina.
In order to improve our knowledge on the processes underlying light induced retinal
degenerations, and as a first step to assess new potential therapeutic targets, the role of A1R in
the degenerative process was studied by modulating its activity with an A1R agonist (cyclopen-
tyladenosine -CPA-) or an A1R antagonist (dipropylcyclopentylxanthine -DPCPX-) in the
LIRD model. The effects of these drugs were studied by Terminal deoxynucleotidyl transferase
dUTP nick end labeling (TUNEL) and activated Caspase-3 Western Blotting (WB), and their
effects on glial reactivity were determined by Glial Fibrillary Acidic Protein (GFAP) immuno-
histochemistry, Western Blot and qRT-PCR. Changes in microglia were studied by Iba1 (ion-
ized calcium binding adaptor molecule 1) and major histocompatibility complex class II
(MHC-II) immunohistochemistry. The effects of these drugs on retinal physiology were deter-
mined by electroretinography (ERG). In order to know the mechanisms involved in A1R mod-
ulatory effect of light induced retinal degeneration, the expression of inflammatory cytokines,
iNOS, and nNOS genes was explored by qRT-PCR.
Materials and methods
Animals
56 Male Sprague Dawley albino rats (body weight 200g, age 60 days) were used. Rats were
obtained from the animal house of the Facultad de Veterinaria, Universidad de Buenos Aires.
Before the pharmacological treatment by intravitreal injections, animals were kept at 12/12 h
light/dark cycles (Lighting level: 80 lux during light period). Animal care was performed in
accordance with the European Community Directive 2010/63/EU of 22 September 2010. The
animal model of continuous illumination and the experimental procedure was approved by
the Institutional Committee for the Use and Care of Laboratory Animals of the Facultad de
Medicina, Universidad de Buenos Aires (“Comite´ Institucional para el Cuidado y Uso de Ani-
males de Laboratorio”, CICUAL, Res. (CD) 2599/2013).
Experimental design
Male Sprague Dawley albino rats were intravitreally injected with either cyclopentyladenosine
(CPA), an A1R agonist; or with dipropylcyclopentylxanthine (DPCPX), an A1R antagonist.
While the right eyes received the mentioned drugs, the left eyes received vehicle (CPA vehicle:
0.9% ClNa w/v in water; DPCPX vehicle: 0.3% DMSO v/v dil in 0.9% NaCl w/v in water) and
were the controls. One hour after intravitreal injections, rats were continuously illuminated
for 1 day (12000 lux). Then the retinas were processed for GFAP immunohistochemistry
(IHC), TUNEL or Western Blotting (WB). Electroretinograms (ERG) were performed previ-
ous to intravitreal injections of drugs and also a week after continuous illumination (Fig 1).
Intravitreal injections protocol
Animals were deeply anestethized with Ketamine (40mg/kg; Ketamina 501, Holliday-Scott SA,
Beccar, Argentina) and Xylazine (5 mg/kg; Kensol1, Laboratorios Ko¨nig SA., Buenos Aires,
Argentina). A drop of 2% lidocaine (Lidocaine1 Richmond divisio´n veterinaria SA, Grand
Bourg, Buenos Aires, Argentina) was administered in each eye for local anaesthesia. Intravitreal
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injections (volume: 5 μl) were performed using a Hamilton syringe (Reno, NV, USA) and a
30-gauge needle. The right eyes received the studied drugs (either cyclopentyladenosine (CPA),
an A1R agonist; or dipropylcyclopentylxanthine (DPCPX), an A1R antagonist) while the left
eyes received vehicle and were the controls (CTL). The final vitreal concentrations achieved
were 0.775 mM for CPA and 0.01 mM for DPCPX. Doses were selected based on previous sci-
entific reports [39, 40] and taking into account that the volume of vitreous of the rat eye is
13.36 ± 0.64 μl [41]. The total amount per eye of CPA and DPCPX injected were 10.35 nano-
moles and 0.13 nanomoles, respectively. To promote a correct healing, an ocular re-epitheli-
zation ointment (Oftalday1, Holliday-Scott SA, Beccar, Buenos Aires; Argentina) was applied
after the injection. After recovery from the procedure, the animals were exposed to 1 day of CI.
Continuous illumination procedure
One hour after intravitreal injections, rats were continuously illuminated for 1 day. Groups of 3
to 5 rats were simultaneously placed in an open white acrylic box of 60 cm x 60cm x 60cm with
12 halogen lamps (12V 50 W each) located on top. Lighting level (12,000 lux) was determined
using a digital illuminance meter. Temperature was maintained at 21˚C. This was repeated to
obtain at least 8 animals for IHC, 4 animals for Western Blot procedures, 5 animals for ERG and
5 animals for qRT-PCR. IHC and Western Blot were performed immediately after CI. Animals
used for ERG studies received a basal ERG previous to intravitreal injections of drugs and a sec-
ond ERG (follow up) a week after CI (Fig 1). All animals were offered food and water ad libitum.
Electroretinography
After overnight adaptation, rats (5 animals per drug treatment) were anesthetized under dim
red illumination with Ketamine (40mg/kg; Ketamina 501, Holliday-Scott SA, Beccar,
Fig 1. Timescale of the continuous illumination procedure. All animals were subjected to intravitreal injections of CPA or DPCPX on right eye and of
vehicle on the left eye. After recovery, animals were continuously illuminated for one day (12000 lux). A group of animals was sacrificed right after the end
of CI and they were processed for either IHC, TUNEL or WB assays. A second group of animals, which had been tested through a basal ERG, was left to
recover for a week after CI and a follow up ERG was performed then.
https://doi.org/10.1371/journal.pone.0198838.g001
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Argentina) and Xylazine (5 mg/kg; Kensol1, Laboratorios Ko¨nig SA., Buenos Aires, Argen-
tina). An ophthalmic solution of Phenylephrine hydrochloride 5% and tropicamide 0.5%
(Fotorretin1, Laboratorios Poen, CABA, Argentina) was used to dilate the pupils. Rats were
placed facing the stimulus at a distance of 25 cm in a highly reflective environment. A refer-
ence electrode was placed in the ear, a grounding electrode was attached to the tail, and a gold
electrode was placed in contact with the central cornea. Recordings were made from both eyes
simultaneously.
Scotopic electroretinograms (ERGs): 20 responses to flashes of unattenuated white light (1
ms, 1 Hz) from a photic stimulator (light-emitting diodes) set at maximum brightness were
recorded with electroretinograph Akonic BIO-PC, Buenos Aires, Argentina. The registered
response was amplified, filtered (1.5-Hz low-pass filter, 500Hz high-pass filter, notch activated)
and data were averaged. The a-wave was measured as the difference in amplitude between the
recording at onset and the through of the negative deflection while the b-wave amplitude was
measured from the trough of the a-wave to the peak of the b-wave. Mean values from each eye
were averaged, and the resultant mean value was used to compute the group means a- and b-
wave amplitudes ± SD.
Oscillatory potentials (OPs): Briefly, the same photic stimulator was used with filters of
high (300 Hz) and low (100 Hz) frequency. The amplitudes of the OPs were estimated by
using the peak-to-trough method [42]. The sum of four OPs was used for statistical analysis.
SDS-PAGE and Western-blotting
Retinas of CPA (n = 4) and DPCPX (n = 4) treated animals were dissected out. Five control
retinas were used on each case (n = 5). Tissues were homogenized (1:3, w/v) in lysis buffer
(100 mM NaCl, 10 mM TrisHCL, 0.5% Triton X-100) plus 50ul of Protease inhibitor cocktail
(Merck KGaA, Darmstadt, Germany). All procedures were carried out at 4˚C. Protein concen-
tration was determined by the Bradford method, with bovine serum albumin as standard,
using a Beckman Spectrophotometer DU-65. Then, 50–100 μl of each sample were mixed 4:1
with 5X sample buffer (10% SDS, 0315 M Tris-HCl, 25% Beta-Mercaptoethanol, 50% Glycerol,
0.2 ml bromophenol blue 0.1%, pH 6.8) and heated for 10 minutes at 100˚C. Samples were run
(50 μg of protein per lane) on SDS–polyacrylamide gels (10% or 15% running gels with 5%
stacking gel), with 0.24 mM TRIS base, 4.38 mM SDS, 0.19 M glycine, pH 8.3, as the electrolyte
buffer. Kaleidoscope Prestained Standards (Bio-Rad Laboratories, California, USA) were used
as molecular weight markers. For Western Blot analysis, proteins were transferred at 100
mVolt for 1 h onto 0.2-μm polyvinylidenedifluoride membranes (GE healthcare life sciences,
Illinois, USA) in a transfer buffer (15% m/v Glycine, 3% m/v TRIS, 20% v/v ethanol).
Membranes were incubated overnight at 4˚C with either a rabbit polyclonal antibody to
GFAP (DAKO Inc., CA, USA; dilution 1:500) or a rabbit polyclonal antibody to activated Cas-
pase 3 (Sigma Chemical Co., MO., USA; dilution 1:100). To test for protein loading accuracy, a
monoclonal anti-β-actin antibody (Sigma Chemical Co., MO., USA, dil: 1: 1000) was used in
the same membranes. To visualize immunoreactivity, membranes were incubated with Amer-
sham ECL Rabbit IgG, HRP-linked F(ab)2 fragment (from donkey), and were developed using
a chemoluminiscence kit (SuperSignal West Pico Chemiluminescent Substrate, Thermo Scien-
tific, Massachusetts, US). Membranes were exposed to X-ray blue films (Agfa Heathcare, Bue-
nos Aires, Argentina), which were developed and then scanned with a HP Photosmart
scanner. Optical density was quantified by Image Studio Light software of Li-Cor. Relative
density is compared to control levels. Differences in actin load were taken in consideration in
each case and data were mathematically corrected in order to obtain the published results.
Data were statistically analysed using Graphpad Software.
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Tissue processing for immunohistochemistry and TUNEL assay
Animals were deeply anaesthetized by intraperitoneal injection of Ketamine (40mg/kg; Keta-
mina 501, Holliday-Scott SA, Beccar, Argentina) and Xylazine (5 mg/kg; Kensol1, Labora-
torios Ko¨nig SA., Buenos Aires, Argentina) and their eyes were removed; the cornea and
lenses were cut off, and the remaining tissues with a cup shape were fixed by immersion in a
solution containing 4% paraformaldehyde in 0.1M phosphate buffer for 24 h. Eyes were
embedded in gelatine, cryoprotected by immersion in a solution containing 30% sucrose in
0.1M phosphate buffer and then frozen. The frozen eyes were cut along a vertical meridional
plane using a Lauda Leitz cryostat, and sections (thickness: 20 μm) were mounted on gelatine
coated glass slides and processed by Immunoperoxidase, immunofluorescence or TUNEL
techniques.
Immunoperoxidase technique
In order to inhibit endogenous peroxidase activity, sections were incubated in methanol con-
taining 3% hydrogen peroxide for 30 min. After washing in phosphate buffered saline (PBS),
pH 7.4, sections were incubated in 10% normal goat serum for 1h. Then, sections were incu-
bated overnight with a previously characterized GFAP polyclonal primary antibody (Dako,
USA, dilution 1:500). The following day, sections were incubated in biotinylated goat anti rab-
bit antibody (Sigma Chemical Co.,MO., USA; dilution 1:500). Following this, sections were
incubated in ExtrAvidin-Peroxidase1 complex (Sigma Chemical Co., MO., USA; dilution
1:500). All antisera were diluted in phosphate-buffered saline (PBS) containing 0.2% Triton
X-100 and, in all but in the peroxidase complex, 1% normal goat serum. Incubations in pri-
mary antibody were performed overnight at 4˚C while incubations in biotinylated antibody,
ExtrAvidin-Peroxidase1 complex were performed at room temperature (RT) for 1h. Controls
were performed by omitting primary antibodies. Development was performed using the DAB/
nickel intensification procedure [43].
Immunofluorescence technique
Sections were incubated overnight with an Iba1 rabbit polyclonal antibody (Thermo Fisher
Scientific Inc., USA, dilution 1:125). The following day, sections were incubated in biotinylated
goat anti rabbit antibody (Sigma Chemical Co.,MO., USA; dilution 1:125), and later in Strepta-
vidin-Alexa Fluor1 635 conjugate (Thermo Fisher Scientific Inc., USA, dilution 1:50). Incu-
bations in biotynilated goat anti rabbit antibody and Streptavidin-Alexa Fluor1 635
conjugate were performed at RT for 1 h. Finally, sections were counterstained with Hoechst
33258 (Sigma Chemical Co., MO., USA) and were observed using an Olympus IX-81 inverted
microscope.
Double labelling technique
Some sections were incubated overnight with a mixture containing a polyclonal rabbit anti-
body to A1R (Santa Cruz Biotech. Inc., USA, dilution 1:50) and a mouse monoclonal antibody
to Iba 1 (Santa Cruz Biotech. Inc., USA, dilution 1:50). Other sections were incubated over-
night with a mixture containing a mouse monoclonal to major histocompatibility complex
class II (MHC-II) (Santa Cruz Biotech. Inc., USA, dilution 1:50) and a rabbit polyclonal anti-
body to Iba 1 (Invitrogen USA, dilution 1:50).
In both cases sections were later incubated in a mixture of goat anti rabbit antibody
conjugated to Alexa Fluor1 488 (Abcam, dilution 1:50) and goat anti-mouse antibody conju-
gated to Alexa Fluor1 555 (Abcam, dilution 1:50) at RT for 1 h. Finally, sections were
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counterstained with Hoechst 33258 (Sigma Chemical Co., MO., USA) and were observed
using an Olympus IX-83 inverted microscope. Simultaneously, negative controls were per-
formed by omitting primary antibodies and their photographs were added to S1 Fig.
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)
assay
Cryostat sections were processed using the ApopTag1 Peroxidase In Situ kit (Millipore,
USA). Briefly, sections were washed in PBS and post-fixed in ethanol:acetic acid (2:1) at -20˚C.
After washing in PBS the endogenous peroxidase was quenched with 3% hydrogen peroxide
solution at RT. After rinsing with distilled water and equilibration buffer, sections were incu-
bated with terminal deoxynucleotidyl transferase for 1 hour at 37˚C. The reaction was stopped
by a supplied buffer and the sections were incubated with anti-digoxigenin conjugate for 30
minutes at RT. Finally sections were developed using DAB/nickel intensification procedure
and were counterstained with eosine.
Image analysis of TUNEL, GFAP immunoperoxidase sections and single or
double labeled microglial cells
Six retinal sections of both eyes from each experimental group were analyzed (CPA, n = 8;
DPCPX n = 8). Care was taken on selecting anatomically matched areas of retina among ani-
mals before assays. Slides were analysed using a Zeiss Axiophot microscope attached to a video
camera (Olympus Q5). Images were taken using Q capture software. To avoid external varia-
tions, all images were taken the same day and under the same light conditions.
The following parameters were measured, blind to treatment, on 8 bits images, using the
Fiji software (NIH, Research Services Branch, NIMH, Bethesda, MD):
GFAP positive area: Images of drug treated and control retinas were randomly selected.
Immunoreactive area of the whole sections was thresholded. The region of interest (ROI) was
the retinal surface between the two limiting membranes where Mu¨ller cells extend their pro-
cesses. The GFAP positive area was calculated as the percentage of the ROI immunostained by
GFAP.
TUNEL positive nuclei/1000μm2: Images of drug treated and control retinas were randomly
selected and thresholded. As region of interest (ROI), frames of 1000 μm2 were randomly
determined on the outer nuclear layer of treated and control retinas. The analyse particles
function of Fiji was used [44] and the TUNEL positive nuclei/1000μm2 ratio was then obtained
in each ROI.
Iba 1 positive microglial cells/10000μm2: Images of drug treated and control retinas were ran-
domly selected and thresholded. As region of interest (ROI), frames of 10000 μm2 were ran-
domly determined on treated and control retinas. The Iba 1 positive microglial cells/10000μm2
ratios were obtained in each ROI.
Iba 1+ /MHC-II+ microglial cells. Images of drug treated and control retinas were quantified.
The number of activated microglia (double labelled as Iba 1+ and MHC-II+ and) was expressed
as the percentage of the total number of Iba 1 positive cells per retinal section.
RNA isolation and quantitative reverse transcription polymerase chain
reaction (qRT-PCR)
Unilluminated rats (basal control), rats submitted to 1 day of CI, CPA and DPCPX treated rats
(n = 5 per group) which were submitted to one day of continuous illumination were deeply
anaesthetized by intraperitoneal injection of Ketamine (40mg/kg; Ketamina 501, Holliday-
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Scott SA, Beccar, Argentina) and Xylazine (5 mg/kg; Kensol1, Laboratorios Ko¨nig SA., Bue-
nos Aires, Argentina) and their retinas were dissected out. In the cases of drug treated rats,
right eyes received the studied drugs (either CPA or DPCPX), while the left eyes received vehi-
cle and were the Controls (CTL). Additional controls were included: Non-illuminated control
rats to evaluate basal gene level expression, and Non-treated rats (CTL) exposed to CI (CI 1d)
in order to evaluate the effect of damage (n = 6, per group). Tissues were homogenized with
TRIzol (Invitrogen, Madrid, Spain) and RNA was isolated with RNeasy Mini kit (Qiagen, Ger-
mantown, MD). Three μg of total RNA were treated with 0.5 μl DNAseI (Invitrogen) and
reverse-transcribed into first-strand cDNA using random primers and the SuperScript III kit
(Invitrogen). Reverse transcriptase was omitted in control reactions, where the absence of
PCR-amplified DNA confirmed lack of contamination from genomic DNA. Resulting cDNA
was mixed with SYBR Green PCR master mix (Invitrogen) for qRT-PCR using 0.3 μM forward
and reverse oligonucleotide primers. Quantitative measures were performed using a 7300 Real
Time PCR System (Applied Biosystems, Carlsbad, CA). Cycling conditions were an initial
denaturation at 95ºC for 10 min, followed by 40 cycles of 95˚C for 15 seconds and 60˚C for 1
minute. At the end, a dissociation curve was implemented from 60 to 95ºC to validate ampli-
con specificity. Gene expression was calculated using absolute quantification by interpolation
into a standard curve. All values were divided by the expression of the house keeping gene 18S.
Statistical analysis
The data of GFAP immunohistochemistry and TUNEL studies of CPA-treated rats (n = 8) and
DPCPX treated rats (n = 8) were obtained by image analysis as was described before. Normal-
ity distribution of the data was evaluated using D´Agostino, KS, Shapiro-Wilk and F tests. In
every case, Gaussian distribution was confirmed. Then, data were analysed using unpaired
parametric Student´s t-test included in the GraphPad software (GraphPad Software, San
Diego, CA). Values are expressed as mean ± standard deviation. In the case of Iba 1 immuno-
histochemistry (IHC) (n = 4 per group), WB (n = 4 per group), ERG (n = 5 per group) and
RT-PCR (n = 5 for CPA and DPCPX; n = 6 for CTL and CI 1d), data distribution was analysed
in the same way and at least one of the used tests confirmed Gaussian distribution, validating
the use of Student´s T test. Values are expressed as mean ± standard deviation. Differences
were considered significant when p<0.05.
Results
CPA decreases apoptotic cell death, glial reactivity and Iba 1+/MHC- II+
microglial cells
No TUNEL positive nuclei were found in control eyes before illumination, but after 1 day of
CI, apoptotic nuclei were found in retinal outer nuclear layer (ONL) in both experimental con-
ditions (CPA and control). However, CPA treated retinas presented a lower number of
TUNEL positive nuclei in the outer nuclear layer than control animals (Fig 2A and 2B). Quan-
tification by image analysis showed an average of 1.454 ± 0.737 apoptotic nuclei per 1000 μm2
in the outer nuclear layer of CPA treated retinas vs 4.25 ± 1.379 apoptotic nuclei per 1000 μm2
in the outer nuclear layer of control retinas. The difference was significant using an unpaired
Student´s t-test (p< 0.001; n = 8) (Fig 2G).
Before illumination, GFAP immunoreactivity was restricted to the end feet of Mu¨ller cells
close to the inner limiting membrane. After illumination GFAP immunoreactivity increased
in Mu¨ller cell processes across the whole retinas and a strong staining was observed in the end
feet close to the inner limiting membrane in both conditions. However, in animals treated
Adenosine A1 receptor: A neuroprotective target in light induced retinal degeneration
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with CPA, Mu¨ller cell processes were thinner and GFAP immunoreactivity of the ending feet
was weaker compared with control, indicating lower levels of glial activation (Fig 2C and 2D).
In fact, image analysis quantification showed a significant decrease of GFAP positive area in
CPA treated retinas (13.02 ± 10.67%) vs control retinas (33.32 ± 15.23%) (unpaired Student´s
t-test; p<0.01; n = 8) (Fig 2H).
CPA treated retinas showed a significant decrease in the number of Iba 1 positive microglial
cells (Fig 2E and 2F). Image analysis quantification showed that the decrease was significant
(CPA: 1.28 ± 0.155 cells/10,000 µ2 vs CTL: 2.68 ± 0.61 cells/10,000 μ2, p<0.01) (Fig 2I). In both
conditions, CPA and Control, double labeling technique using primary antibodies to A1
receptor and Iba 1 showed the co-localization of the A1 receptor and Iba1 on microglial cells
(Fig 3, Top and second row, and Fig 4). In order to detect reactive microglia, double labeling
technique using primary antibodies to Iba 1 and MHC-II was performed (Fig 4, Top and sec-
ond rows). CPA treated retinas showed a significant decrease of the percentage of reactive
microglial cells (Iba 1+ and MHC-II +) compared to control (p< 0.05) (Fig 5).
DPCPX increases apoptotic cell death, glial reactivity and Iba 1+ /MHC-II+
microglial cells
In contrast with the results observed with CPA, after the illumination procedure a higher num-
ber of TUNEL positive nuclei was observed in the outer nuclear layer of DPCPX treated eyes
versus control (Fig 6A and 6B). Quantification by image analysis showed an average of
6.755 ± 2.337 apoptotic nuclei per 1000 μm2 in the outer nuclear layer of DPCPX treated reti-
nas vs 3.608 ± 1.402 apoptotic nuclei per 1000 μm2 in control retinas. The difference was sig-
nificant using an unpaired Student´s t-test (p< 0.05; n = 8) (Fig 6G).
An increase in GFAP immunoreactivity was observed in DPCPX treated retinas compared
to their controls (Fig 6C and 6D). In animals treated with DPCPX, Mu¨ller cell processes were
thicker and their ending feet close to the inner limiting membrane were bigger and more
intensely stained than those observed in control, indicating a rise of glial activation (compare
Fig 6C and 6D). In fact, image analysis quantification showed a significant increase of the per-
centage of GFAP positive area in DPCPX treated retinas (45.75 ± 16.1%) vs their respective
controls (31.69 ± 10.15%) (unpaired Student´s t-test; p = 0.05; n = 8) (Fig 6H).
DPCPX treated retinas showed a significant increase in the number of Iba 1 positive micro-
glial cells compared to controls (Fig 6E and 6F). Image analysis quantification showed that the
increase was significant (DPCPX: 3.235 ± 1.356 cells/10,000 μ2 vs CTL: 1.80 ± 0.89 cells/
10,000 μ2, p< 0.05) (Fig 6I). In both conditions, DPCPX and Control (Fig 3, third and fourth
row), double labeling technique using primary antibodies to A1 receptor and Iba 1 showed the
co-localization of the A1 receptor and Iba1 on microglial cells. In order to assess reactive
Fig 2. CPA treatment decreases cell death, Mu¨ller cell activation and microglial infiltration. A-B) Microphotograph of
representative sections showing TUNEL staining of the outer nuclear layer (ONL) of CPA treated eye (A) and Control eye (B).
Only two positive apoptotic nuclei may be observed in the field of CPA treated eye (A) while a huge number of apoptotic nuclei
are observed in CTL eye (B). Scale bar: 20μm. C-D) Microphotograph of GFAP immunostained sections of CPA treated eye (C)
and Control eye (D). Thin processes of Mu¨ller cells are observed in the retina of CPA treated eye (C) while thicker processes of
Mu¨ller cells are observed in the retina of CTL eye (D).Scale bar: 20μm. E-F) Microphotograph of Hoechst (left, blue) and IBA1
(right, red) stained sections of a CPA treated eye (E) and Control eye (F). A lesser number of IBA1 positive cells are observed in
the retina of CPA treated eye (E) while more cells are present in the retina of CTL eye. Scale bar: 20μm. G) Quantification of ONL
TUNEL positive cells. CPA treatment produced a significant decrease of ONL positive nuclei when compared to CTL
(1.454 ± 0.7376 vs 4.25 ± 1.379 apoptotic nuclei per 1000 μm2; unpaired Student´s t-test p<0.001; n = 8). p<0.001. H)
Quantification of GFAP positive area staining. CPA treatment produced a significant decrease of GFAP expression when
compared to CTL (13.02±10.67% vs control retinas 33.32±15.23%; unpaired Student´s t-test; p<0.01; n = 8). p<0.01. I)
Quantification of IBA1 positive cells. CPA treatment produced a significant decrease of IBA1 positive cells when compared to
CTL (1.283 ± 0.1554 vs 2.683 ± 0.6115 IBA1 positive cells per 10000 μm2; unpaired Student´s t-test p<0.01; n = 4). p<0.01.
https://doi.org/10.1371/journal.pone.0198838.g002
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microglia, double labeling technique using primary antibodies to Iba 1 and MHC-II was per-
formed (Fig 4, third and fourth rows). DPCPX treated retinas showed a highly significant
increase of the percentage of reactive microglial cells (Iba 1+ and MHC-II +) compared to con-
trol (p< 0.01) (Fig 5).
Effect of CPA and DPCPX on activated Caspase 3 and GFAP expression by
Western blot assays
In CPA treated eyes, lower levels of activated Caspase 3 protein were detected compared to
control (CPA = 0.6527 ± 0.03 vs control = 0.996± 0.04; unpaired Student´s t-test; p< 0.01;
t = 5.834; n = 4) (Fig 7A and 7E and S2 and S3 Figs).
GFAP protein levels were significantly lower in the CPA treated eyes (0.652 ± 0.117) than
in control eyes (0.993 ± 0.1329) (unpaired Student´s t-test; p<0.01; t = 3.53; n = 4), (Fig 7A
and 7C and S2 and S3 Figs).
The results of Western Blot assays were in accordance to those observed with TUNEL tech-
nique and immunohistochemistry. In DPCPX treated eyes, higher levels of activated Caspase 3
(1.85 ± 0.5 vs 1.01 ± 0.07; unpaired Student´s t-test; p<0.01; t = 3.385; n = 4), and GFAP
(3.785 ± 2.515 vs 1.00 ± 0.108; unpaired Student´s t-test; p<0.05; t = 2.2885; n = 4) were found,
thus confirming the presence of more apoptosis and an increase of glial reactivity, respectively
(Fig 7B, 7D and 7F and S2 and S3 Figs).
Effect of CPA and DPCPX on scotopic electroretinograms and oscillatory
potentials
A week after the CI exposure for 1 day, control eyes showed decreases in b-wave amplitude
and oscillatory potential sum compared with their respective basal values (Fig 8C and 8D and
Fig 9A and 9B). However, at the same time point, CPA treated eyes showed an increased
amplitude for the a-wave and similar b-wave and oscillatory potentials compared to basal val-
ues measured before CI (Fig 8A and 8B and Fig 9A and 9B and Table 1).
When compared to control eyes, after exposure to continuous illumination, CPA treated
eyes showed significantly higher amplitudes of all the electrophysiological parameters: a-wave
(14.07 ± 3.56 µV vs 7.14 ± 0.63, unpaired Student´s t-test; p<0.05, t = 3.247) (Fig 8E), b-wave
(106 ± 57.9 μV vs 60.11 ± 37.37 µV; unpaired Student´s t-test; p<0.05, t = 2.82) (Fig 8F), and
oscillatory potential sum (Figs 7 and 9C) (36.87 ± 9.58 μV vs 26.88 ± 7.5 μV, unpaired Student´s
t-test; p<0.05, t = 2.639).
In summary, continuous illumination induced an electrophysiological damage that was
avoided by CPA treatment.
As mentioned above, a week after the continuous illumination exposure for 1 day, control
eyes showed a decrease on the amplitude of the a-wave, b-wave (Fig 10C and 10D), and the
oscillatory potentials sum (Fig 11A and 11B), compared with basal values measured before
continuous illumination (Table 2).
After comparing DPCPX control eyes, illuminated for 1 day, with CPA control eyes illumi-
nated for 1 day, a more important decrease of a-wave was observed which may be consequence
of the drug vehicle (DMSO) which used to dissolve the DPCPX [45].
Fig 3. Double immunolabeling for Iba 1 and A1 receptor. Representative sections of CPA Control retina (top row); CPA
treated retina (second row); DPCPX Control retina (third row) and DPCPX treated retina (fourth row). In every case nuclear
staining with Hoechst 33258 (blue), A1 receptor immunolabeling (green); Iba 1 immunolabeling (red), and double labeling of
the same sections may be observed form left to right. Insets show higher magnifications of merge images. Scale bars = 20 μm.
https://doi.org/10.1371/journal.pone.0198838.g003
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DPCPX treated eyes also showed decreases of the a-wave, b-wave, and oscillatory potential
sum when compared to basal values measured before continuous illumination (Fig 10A and
10B, Fig 11A and 11B and Table 2).
When compared to control eyes after illumination, DPCPX eyes did not show significant
differences in the amplitudes of the a-wave (Fig 10E, unpaired Student´s t-test, p = 0.61,
t = 0.5486), b-wave (Fig 10F, unpaired Student´s t-test, p = 0.16, t = 1.079), or oscillatory
potential sum (Fig 11C, unpaired Student´s t-test, p = 0.49, t = 0.02184).
In summary, illumination showed a deleterious effect on retinal function which was neither
worsened nor prevented by DPCPX.
Effect of CPA and DPCPX on the expression of nNOS, iNOS, IL-1β, TNFα
and GFAP mRNAs
Quantitave RT-PCR technique showed highly significant increases of nNOS, GFAP and TNFα
mRNAs in non-treated rats exposed to 1d of CI compared to basal values (Fig 12). Also a sig-
nificant increase of IL-1β mRNA was detected in this group but the method was unable to
show a significant increase of iNOS. However, a significant decrease of iNOS mRNA expres-
sion was demonstrated in the retinas of CPA treated eyes compared to control (0.6990±0.4799
vs 1.322±0.7427, unpaired Student´s t-test, p<0.05, n = 5) while nNOS expression did not
Fig 4. Double immunolabeling for Iba 1 and MHC-II. Representative sections of CPA Control retina (top row); CPA treated
retina (second row); DPCPX Control retina (third row) and DPCPX treated retina (fourth row). In every case nuclear staining
with Hoechst 33258 (blue), Iba 1 immunolabeling (green), MHC II immunostaining (red) and double labeling (merge) of the
same sections may be observed form left to right. Insets show higher magnifications of merge images. Arrow heads show
reactive microglial cells. Observe the low number of double stained reactive microglial cells in CPA treated retina and the higher
number of double stained reactive microglial cells in DPCPX treated retina. Scale bars = 20 μm and 5μm (inset).
https://doi.org/10.1371/journal.pone.0198838.g004
Fig 5. Quantification of double immunolabeling for Iba 1 and MHC-II. The number of activated microglia (Iba 1+/ MHC-II+) was expressed as the percentage of
the total number of Iba 1+ microglial cells per section. CPA treated retinas showed a significant decrease of reactive microglial cells (p<0.05) while DPCPX treated
retinas showed a highly significant increase of reactive microglial cells (p<0.01).
https://doi.org/10.1371/journal.pone.0198838.g005
Adenosine A1 receptor: A neuroprotective target in light induced retinal degeneration
PLOS ONE | https://doi.org/10.1371/journal.pone.0198838 June 18, 2018 14 / 28
Adenosine A1 receptor: A neuroprotective target in light induced retinal degeneration
PLOS ONE | https://doi.org/10.1371/journal.pone.0198838 June 18, 2018 15 / 28
change (Fig 12). Also the levels of inflammatory cytokine TNFα significantly decreased in the
retinas of CPA treated eyes compared to control (0.8903±0.4123 vs 1.510±0.6335; unpaired
Student´s t-test, p<0.05, n = 5). GFAP mRNA expression was also diminished by CPA (0.7582
±0.2721 vs 1.17±0.2728; unpaired Student´s t-test, p<0.05, n = 5). Levels of IL-1β did not
change significantly (Fig 12). No significant changes were detected by qRT-PCR in any of the
four genes studied when comparing the retinas of DPCPX treated eyes with their controls (Fig
12).
Discussion
In the present work, we studied the effect of the intravitreal administration of an A1R agonist
(CPA) and an A1R antagonist (DPCPX) on light induced retinal degeneration. Although a less
invasive treatment could be implemented, intravitreal administration ensured achieving the
intended drug concentration in the retinal tissue, as published [39, 40]. In patients suffering
the wet variant of AMD, intravitreal injection is the common way of administrating the anti-
VEGF treatment.
In our study, the decrease of TUNEL staining in the outer nuclear layer induced by CPA
treatment clearly shows a neuroprotective role for A1 receptor agonists on photoreceptors.
Neuroprotection is further confirmed by Western Blot analysis which shows a decrease of acti-
vated Caspase 3 levels. In addition, the results show a decrease of Mu¨ller cell activation as
GFAP diminishes both by RT-PCR (mRNA), immunohistochemistry and Western Blot, sup-
porting further evidence of a neuroprotective action through avoidance of glial reactivity. This
effect may also be regarded as part of an antiinflammatory action. In fact, qRT-PCR results
showed a significant diminution of the inflammatory cytokine TNFα and iNOS.
So, the administration of an A1 agonist shows a neuroprotective effect through mechanisms
that prevented photoreceptor apoptotic cell death, a reduction of microglial response, demon-
strated by a reduction in iNOS and TNFα mRNA expression, and a decrease of glial reactivity,
as demonstrated by GFAP immunoreactivity, Western Blot and qRT-PCR. In order to confirm
that CPA induced a reduction of microglial reactivity, retinas were stained with Iba 1 (ionized
calcium adaptor molecule 1). Iba 1 is a microglial and macrophage-specific calcium-binding
protein involved in the reorganization of actin cytoskeleton through Rac signaling pathway
[46]. Iba 1 is involved in membrane ruffling and phagocytosis in activated microglia [47] and
was previously used as a marker of reactive microglia after transient focal cerebral ischemia
[48]. Our results showed a significant reduction of Iba1+ microglial cell population in CPA
treated retinas while, on the opposite, DPCPX induced a highly significant increase of Iba 1+
microglial cells. Double labeling experiments showed the co-existence of A1R and Iba 1 dem-
onstrating the direct effect of the agonists on microglial cells. As major histocompatibility
Fig 6. DPCPX increases cell death, Mu¨ller cell activation and microglial infiltration. A-B) Microphotograph of
representative sections showing TUNEL staining of the outer nuclear layer of the retina of a DPCPX treated eye (A) and of a
CTL eye (B). Observe the important number of apoptotic nuclei in DPCPX treated eye (A) compared to the number of
apoptotic nuclei present in CTL eye (B). Scale bar: 20μm. C-D) Microphotograph of GFAP immunostained sections of the
retina of a DPCPX treated eye (C) and of a control eye (D). Higher immunoreactivity of Mu¨ller cells are observed in the retina
of DPCPX treated eye (C) compared to Mu¨ller cells in the retina of CTL eye (D).Scale bar: 20μm. E-F) Microphotograph of
Hoechst (left, blue) and IBA1 (right, red) stained sections of a DPCPX treated eye (E) and Control eye (F). A higher number of
IBA1 positive cells are observed in the retina of DPCPX treated eye (E) compared to those observed in the retina of CTL eye
Scale bar: 20μm. G) Quantification of ONL TUNEL positive cells. DPCPX produced a significant rise in ONL positive nuclei
when compared to CTL (6.755±2.337 vs 3.608±1.402; unpaired Student´s t-test; p<0.05; n = 8). p< 0.05. H) Quantification of
GFAP positive area staining. DPCPX produced a significant rise in GFAP expression when compared to CTL (45.75±16.1% vs
31.69±10.15%; unpaired Student´s t-test; P<0.05; = 4). p< 0.05. I) Quantification of IBA1 positive cells. DPCPX treatment
produced a significant increase of IBA1 positive cells when compared to CTL (3.235 ± 1.356 vs 1.801 ± 0.8941 IBA1 positive
cells per 10000 μm2; unpaired Student´s t-test p<0.05; n = 4). p<0.05.
https://doi.org/10.1371/journal.pone.0198838.g006
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Fig 7. CPA treatment lowered activated caspase 3 and GFAP levels while DPCPX increased activated Caspase 3 and GFAP levels. A) Representative
Western Blot of CPA and CTL treated eyes (cropped blots are displayed). From top to bottom bands correspond to GFAP, Actin and C3a. B) Representative
Western Blot of DPCPX and CTL treated eyes (cropped gels/blots are displayed). From top to bottom bands correspond to GFAP, Actin and C3a. C)
Quantification of GFAP by WB. CPA produced a highly significant decrease of GFAP relative density compared to CTL (0.652 ± 0.117 vs 0.993 ± 0.1329;
unpaired t-test; p<0.01; n = 4), p<0.01. D)Quantification of GFAP by WB. DPCPX produced a significant rise in GFAP relative density compared to CTL
(3.785 ± 2.515 vs 1.00 ± 0.108; unpaired Student´s t-test; p<0.05; n = 4), p< 0.05. E) Quantification of C3a by WB. CPA produced a highly significant decrease
of C3a relative density compared to CTL (0.6527±0.03 vs 0.996±0.04; unpaired Student´s t-test; P = 0.001; n = 4), p<0.01. F) Quantification of C3a by WB.
DPCPX produced a highly significant rise in C3a relative density compared to CTL (1.85±0.5 vs 1.01±0.07; unpaired Student´s t-test; p<0.01; n = 4), p<0.01.
https://doi.org/10.1371/journal.pone.0198838.g007
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Fig 8. Effect of CPA treatment on ERG recordings (I): a-wave and b-wave. A) Basal ERG response of a CPA treated eye. B) ERG response
a week after CI of a CPA treated eye. Observe a small increase of a-wave amplitude and the preservation of b-wave amplitude compared to
Basal ERG (A). C) Basal ERG response of CTL eye. D) ERG response a week after CI of a CTL eye. Observe a decrease of both a-wave
amplitude and b-wave amplitudes. E) Quantification of a-wave amplitude of both eyes a week after injection and 1d of CI. A significant
higher amplitude of of a-wave was detected in CPA treated eyes compared to CTL eyes (14.07 ± 3.56 μV vs 7.14 ± O.63, unpaired Student´s t-
test; p<0.05; n = 5), p< 0.05. F) Quantification of b-wave amplitude of both eyes a week after injection and 1d of CI. A significant higher
amplitude of b-wave was detected between CPA treated eyes compared to CTL eyes (106 ± 57.9 μV vs 60.11 ± 37.37 µV; unpaired Student´s
t-test; p<0.05; n = 5), p< 0.05.
https://doi.org/10.1371/journal.pone.0198838.g008
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Fig 9. Effect of CPA treatment on ERG recordings (II): Oscillatory potentials. A) Basal Oscillatory potentials
response of a CPA treated eye (top) and of a CTL eye (bottom). B) Oscillatory potentials response a week after after 1d
of CI of a CPA treated eye (top) and of a CTL eye (bottom). C) Quantification of oscillatory potentials sum amplitude
of both eyes (CTL and CPA) a week after injection and 1d of CI. A significant difference was detected between CPA
and CTL eyes (36.87 ± 9.58 µV vs 26.88 ± 7.5 μV, unpaired Student´s t-test; p<0.05; n = 5), p< 0.05.
https://doi.org/10.1371/journal.pone.0198838.g009
Table 1. ERG recordings of control and CPA treated eyes.
CONTROL EYE CPA TREATED EYE
BASAL ILLUMINATED BASAL ILLUMINATED
a-wave (μV) 10.61 ± 6.27 7.14 ±0.63 9.88 ± 3.38 14.07 ± 3.56
b-wave (μV) 140.2 ± 72.16 60.11 ± 37.37 137.4 ± 50.53 106 ± 57.9
OP (μV) 35.87 ± 13.56 26.88 ± 7.5 33.10 ± 7.18 36.87 ± 9.58
Observe that recordings from CPA illuminated eyes differ significantly from control illuminated eyes (, p<0.05).
https://doi.org/10.1371/journal.pone.0198838.t001
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Fig 10. Effect of DPCPX treatment on ERG recordings (I): a-wave and b-wave. A) Basal ERG response of a DPCPX treated eye. B) ERG
response a week after 1d of CI of a DPCPX treated eye. Observe a decrease in the amplitude of both a-wave and b-wave compared to Basal
ERG (A). C) Basal ERG response of CTL eye. D) ERG response a week after CI of a CTL eye. Observe a decrease of both a-wave amplitude
and b-wave amplitudes. E) Quantification of a-wave amplitude of both eyes a week after injection and 1d of CI. No significant difference
was detected from basal levels after exposure to CI. F) Quantification of b-wave amplitude of both eyes a week after injection and 1d of CI.
No significant difference was detected from basal levels after exposure to CI.
https://doi.org/10.1371/journal.pone.0198838.g010
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Fig 11. Effect of DPCPX treatment on ERG recordings (II): Oscillatory potentials. A) Basal Oscillatory potentials
response of a DPCPX treated eye (top) and of a CTL eye (bottom). B) Oscillatory potentials response a week after 1d of
CI of a DPCPX treated eye (top) and of a CTL eye (bottom).C) Quantification of oscillatory potentials sum amplitude of
both eyes (DPCPX and CTL) a week after injection and 1d of CI. No significant difference was detected between DPCPX
treated eyes and CTL eyes.
https://doi.org/10.1371/journal.pone.0198838.g011
Table 2. ERG recordings of control and DPCPX treated eyes.
CONTROL EYE DPCPX TREATED EYE
BASAL ILLUMINATED BASAL ILLUMINATED
a-wave (μV) 10.61 ± 6.27 2.89 ± 3.04 9.38 ± 3.38 3.8 ± 1.27
b-wave (μV) 140.2 ± 72.16 62.81±31.66 137.4 ± 50.53 85.69 ± 28.21
OP (μV) 35.87 ±13.56 21.71 ± 9 33.10 ± 7.18 19.5 ± 5.54
Observe that recordings from DPCPX illuminated eyes did not differ significantly from control illuminated eyes.
https://doi.org/10.1371/journal.pone.0198838.t002
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complex class II (MHC-II) has been used to detect reactive microglia [36] we performed dou-
ble labeling for Iba 1 and MHC-II. Our results showed a decrease of the reactive microglial
cells (Iba 1+/MHC-II+) in CPA treated retinas compared to controls and an increase of reactive
microglial cells (Iba 1+/MHC-II+) in DPCPX treated retinas compared to controls. These
results are in agreement with previous reports that showed that the activation of A1 receptor
inhibits the morphological activation of microglia [49] and attenuates neuroinflammation and
demyelination in a model of multiple sclerosis [50].
In a similar way, the blockade of A2A receptor in an animal model of ischemia reperfusion
attenuated microglial reactivity and the increased expression and release of proinflammmatory
cytokines and afforded protection to the retina [36, 37].
Although microglia is involved in the inflammatory reaction in the retina producing
inflammatory cytokines as TNFα, other sources of TNFα may be other resident activated mac-
rophages, as well as CD4+ lymphocytes and natural killer cells which arrive to the retinal tissue
by the blood vessels. Also Mu¨ller cells and retinal pigmented cells have been reported to pro-
duce TNFα in autoimmune uveoretinitis [51] so these cells may also contribute to the inflam-
matory response and their role cannot be ruled out.
The changes in ERG response support the idea that A1 modulation impacts not only on
photoreceptor survival but also on the functionality of photoreceptors themselves and of other
inner retina cell types (mainly bipolar and ganglion cells) as a-wave, b-wave, and oscillatory
potentials were protected by CPA pretreatment. On the contrary, DPCPX, an A1R antagonist,
worsened biochemical parameters and two of the studied morphological parameters (apopto-
tic nuclei and GFAP area). In addition, A1 antagonist, DPCPX, was unable to alter gene
expression of iNOS, nNOS or inflammatory cytokines IL-1β and TNFα. It may be speculated
that higher doses of DPCPX, or a longer time of exposure to the drug may alter retinal physiol-
ogy. An alternative explanation may be that the A1R antagonist, DPCPX, lacks its effect in the
absence of an increased A1 receptor activity which could play a part in the CI model
pathophysiology.
The obtained results are in accordance with other reports on the role of adenosine in retinal
neuroprotection mediated by A1 or A2A receptors [38, 35].
However, other questions remain to be answered, such as how the changes in A1R activa-
tion are connected with the apoptosis of photoreceptors, inflammation and glial reactivity.
In the model of LIRD, the administration of an A1R agonist could protect the retina
through the presynaptic inhibition of glutamate release and the modulation of NMDA recep-
tor activity as was previously demonstrated in rat hippocampus [52].
In rod photoreceptors, the observed neuroprotective effect of CPA could be mediated by
the inhibition of calcium influx as it is known that adenosine inhibits calcium influx through
L-type calcium channels [53]. Also the observed protective effect of CPA on photoreceptors
could be mediated by its antioxidant effect as CPA inhibits lipid peroxidation and potentiates
the antioxidant defense mechanisms (peroxidase and catalase enzymes) [54]. In addition, the
activation of A1 receptors inhibits adenylate cyclase (AC) and decrease intracellular cAMP
concentration. These changes decrease cell metabolism and neuronal energy requirements
enhancing cell survival [54, 55].
Fig 12. qRT-PCR of nNOS, iNOS, IL-1β and TNF α and GFAP mRNAs. Figures show mRNA expression of the retinas of unilluminated
rats (Basal control), rats exposed to 1d of CI (CI 1d) and of rats treated with CPA or DPCPX or vehicle solutions (CTL CPA or CTL DPCPX)
and then exposed to 1d of CI. Values are compared to their respective controls. Determinations were performed after exposure of the rat to
one day of continuous illumination. A) nNOS, B) iNOS, C) IL-1β, D) TNF α and E) GFAP, bars represent mean ± SD, unpaired Student´s t-
test, p< 0.05, p<0.001.
https://doi.org/10.1371/journal.pone.0198838.g012
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Adenosine transmission also plays a role directly on the immune response. Higher A1 activ-
ity is necessary to diminish the immune response and promote cell survival [56]. So, we specu-
late that the neuroprotective role of CPA in LIRD could also be mediated through an effect on
the immune response as well. Although the immune response is a late event in other models of
retinal degeneration, our results clearly showed that CPA induced a significant decrease of Iba
1 reactive microglial cell population, and a decrease of iNOS and TNF α mRNAs in this model
of light induced retinal degeneration. Besides, IL-1β is responsible of triggering glial reactivity
[57, 58] which was decreased in our model of LIRD by the treatment with CPA.
In addition, adenosine transmission works in coordination with other signalling systems
that involve the production of trophic factors. A complex crosstalk between IL-6, A1R, and
A2AR stimulates BDNF production and has been shown to protect retinal ganglion cells in
vitro [59, 60].
A cardiovascular effect could also be involved among the neuroprotective mechanisms
mediated by adenosine A1 receptors, as was demonstrated in retinal ischemic insults that
adenosine induces hyperhemia that protects neurons from glutamate toxicity [34].
As consequence of our findings a new strategy using A1 agonists could be used to prevent
retinal degeneration. Knowing that AMD disease starts in one eye and usually progresses to
the other one; the second eye could be protected after the diagnosis. However, Adenosine
receptors can be found in most cells, widely distributed through the body, so the agonist will
act not only on cells involved in the disease but also on cells involved in different physiological
processes [61].
As adenosine receptors are present in most cells, and agonists have adverse effects, includ-
ing sedation, headache, vasodilation, atrioventricular block, and bronchoconstriction [62, 63];
therapeutic strategies should target these receptors only when and where agonists are needed
[61]. In order to do this we considered that CPA locally administered (intravitreal injection) is
the best option, producing less collateral effects. The same concept is behind actual treatments
of AMD that also use intravitreal injections of monoclonal antibodies against VEGF.
Although, in our study the administration of CPA was given preventively before illumina-
tion, it could be administered after illumination to treat retinal degeneration but further stud-
ies are needed to confirm if it is useful as a therapeutic agent in this case.
The present study shows evidence supporting that adenosine, acting through A1 receptors,
is an important factor in degenerative diseases of the eye and its modulation may be used as a
neuroprotective strategy. However, a single treatment with CPA, an A1 agonist, reported here
did not accomplish a total prevention of retinal degeneration. Thence a repetition of the treat-
ment could be considered as well as a combination with other drugs and/or trophic factors.
Although further work is needed to confirm our hypothesis, the modulation of A1 receptor
has a translational value as it could be a useful strategy to prevent the progression of AMD and
other degenerative diseases in humans.
In this work we have shown that a single pharmacological intervention previous to the
beginning of the photic damage was able to swing the retinal fate in opposite directions. While
CPA, an A1 agonist, shows a retinal neuroprotective effect; DPCPX, an A1 antagonist, wors-
ened many of the parameters chosen to assess damage. These results propose a protective role
for A1 activation in LIRD in accordance with other models of retinal degenerative diseases.
Furthermore, LIRD is a valid model for an acquired degenerative disease of the outer retina,
since it recapitulates many of the human symptoms of AMD, such as non-classic transmission
and its pleiotropic effects on different cell types involved in inflammation, apoptotic cell death
and normal neuronal function.
In summary, adenosine and the activation of the A1 receptor are promising targets to
accomplish neuroprotection in LIRD and, hopefully, in retinal degenerative diseases.
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Supporting information
S1 Fig. Negative controls of double immunolabeling for Iba 1/A1R (top row) and for Iba 1/
MHC-II (second row). Representative sections of Control retinas in which primary antibodies
were omitted. In every case sections were incubated with, goat anti rabbit antibody conjugated
to Alexa Fluor1 488 and goat anti-mouse antibody conjugated to Alexa Fluor1 555. In every
case background images are shown as well as their corresponding merge images. Scale
bars = 20 μm.
(TIF)
S2 Fig. Representative Western blots of CPA, DPCPX treated eyes and their respective
controls.
(TIF)
S3 Fig. Representative Western blots of CPA, DPCPX treated eyes and their respective
controls.
(TIF)
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